Anthrax and small pox replikins and methods of use

Details Anthrax and small pox replikins and methods of use Anthrax and small pox replikins and methods of use

2007-02-13

2007-02-13

Campell, Bruce R. (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C424S246100

Reexamination Certificate

active

09984056

ABSTRACT:
Isolated peptides of theBacillus anthracisAnthrax Toxin Lethal factor Protein pX01–107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to theBacillus anthracisAnthrax Toxin Lethal factor Protein pX01–107 are disclosed. Also disclosed are isolated peptides of the Small Pox Virus Surface Antigen S Precursor Protein, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Small Pox Virus Surface Antigen S Precursor Protein.

REFERENCES:
patent: 5104854 (1992-04-01), Schlesinger et al.
patent: 5231167 (1993-07-01), Zanetti et al.
patent: 5866690 (1999-02-01), Bogoch
patent: 6242578 (2001-06-01), Bogoch et al.
patent: WO 00/18351 (2000-04-01), None
NCBI listing JQ0032, residues 74- 82.
NCBI listing JQ0032, residues 74- 82, May 11, 2000.
Database Medline on STN, National Library of Medicine, (Bethesda, MD, USA), No. 89028479, Bogoch et al.:In vitro production of the general transformation antibody related to survival in human cancer patients; antimalignin antibody; Abstract, Cancer Detection and Prevention, 1988, vol. 12, Nos. 1-6, pp. 313-320.
Andrew D. Pannifer, et al. “Crystal structure of the anthrax lethal factor,”Nature, vol. 414, p. 229-233, (Nov. 2001).
Ping Zhao, et al. “Neutralizing monoclonal antibody against Anthrax lethal factor inhibits intoxication in a mouse model,”Human Antibodies, vol. 12, p. 129-135, (2003).
Ya Ping Shi, et al., “Immunogenicity andin vitroprotective efficacy of a recombinant multistagePlasmodium falciparumcandidate vaccine,”Proc. Natl. Acad. Sci., vol. 96, pp. 1615-1620, (Feb. 1999).
Xiao-Ming Gao, et al., “Identification and Characterization of T Helper Epitopes in the Nucleoprotein of Influenza A Virus,”The Journal of Immunology, vol. 143, No. 9, pp. 3007-3014, (Nov. 1999).
Toby C. Rodman, et al., “Human Immunodeficiency Virus (HIV) Tat-reactive Antibodies Present in Normal HIV-negative Sera and Depleted in HIV-positive Sera. Identification of the Epitope,” vol. 175, pp. 1247-1253, (May 1992).
Brown, L. R. et al., “Recognition of the influenza hemagglutinin by Class II MHC-restricted T lymphocytes and antibodies,”Journal of Immunology, Oct. 15, 1991, pp. 2677-2684, vol. 147, No. 8, American Association of Immunologists, USA, XP002371257, ISSN: 0022-1767.
Atassi, M. Z. et al., “A novel approach for localization of the continuous protein antigenic sites by comprehensive synthetic surface scanning: Antibody and T cell activity to several influenza hemagglutinin synthetic sites,”Immunological Communications, 1984, pp. 539-551, vol. 13, No. 6, Marcel Dekker, Inc., XP009062995, ISSN: 0090-0877.
Carr, C. M. et al., “A spring-loaded mechanism for the conformational change of influenza hemagglutinin,”Cell, May 21, 1993, pp. 823-832, vol. 73, Cell Press, XP002059698, ISSN: 0092-8674.
Ben-Yedidia, T. et al., “Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection,”International Immunology, 1999, pp. 1043-1051, XP000914818, ISSN: 0953-8178.
Schenk, S. et al., “Four recombinant isoforms ofCor a1, the major allergen of hazel pollen, show different reactivities with allergen-specific T-lymphocyte clones,”European Journal of Biochemistry, 1994, pp. 717-722, vol. 224, XP002371408, ISSN: 0014-2956.
Orlando, C. et al., “A monoclonal antibody directed against the catalytic site ofBacillus anthracisadenylyl cyclase identifies a novel mammalian brain catalytic subunit,”Biochemistry, 1992, pp. 3215-3222, vol. 31, American Chemical Society, XP002371438, ISSN: 0006-2960.

Affiliated with

Also associated with

Rating

Anthrax and small pox replikins and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anthrax and small pox replikins and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anthrax and small pox replikins and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3871114